X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3084) 3084
Book Review (1070) 1070
Publication (179) 179
Book Chapter (14) 14
Magazine Article (12) 12
Conference Proceeding (7) 7
Newspaper Article (5) 5
Newsletter (3) 3
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2596) 2596
index medicus (2526) 2526
dabigatran (2358) 2358
warfarin (1533) 1533
anticoagulants - adverse effects (1343) 1343
anticoagulants (1291) 1291
rivaroxaban (1160) 1160
male (1079) 1079
atrial fibrillation (1051) 1051
female (1010) 1010
anticoagulants - therapeutic use (998) 998
aged (976) 976
administration, oral (960) 960
atrial fibrillation - drug therapy (881) 881
anticoagulants - administration & dosage (874) 874
hemorrhage - chemically induced (865) 865
stroke (830) 830
apixaban (716) 716
dabigatran etexilate (710) 710
stroke - prevention & control (692) 692
risk factors (656) 656
beta-alanine - analogs & derivatives (653) 653
cardiac & cardiovascular systems (637) 637
middle aged (636) 636
benzimidazoles - adverse effects (632) 632
prevention (600) 600
atrial-fibrillation (598) 598
treatment outcome (594) 594
atrial fibrillation - complications (585) 585
venous thromboembolism (544) 544
aged, 80 and over (536) 536
hematology (503) 503
peripheral vascular disease (491) 491
warfarin - adverse effects (488) 488
antithrombins - adverse effects (485) 485
thromboembolism (466) 466
beta-alanine - adverse effects (463) 463
pharmacology & pharmacy (463) 463
dabigatran - adverse effects (458) 458
benzimidazoles - therapeutic use (451) 451
warfarin - therapeutic use (402) 402
management (401) 401
risk (392) 392
medicine, general & internal (389) 389
abridged index medicus (387) 387
anticoagulation (386) 386
safety (385) 385
stroke - etiology (383) 383
stroke prevention (373) 373
bleeding (372) 372
therapy (371) 371
benzimidazoles - administration & dosage (362) 362
drug therapy (328) 328
thrombin (324) 324
direct thrombin inhibitor (317) 317
hemorrhage (315) 315
oral anticoagulants (312) 312
cardiac arrhythmia (311) 311
beta-alanine - therapeutic use (307) 307
analysis (300) 300
medicine & public health (296) 296
pyrazoles - adverse effects (296) 296
pyridones - adverse effects (296) 296
care and treatment (291) 291
blood coagulation - drug effects (286) 286
pyrazoles - therapeutic use (285) 285
pyridones - therapeutic use (285) 285
vitamin k - antagonists & inhibitors (280) 280
dabigatran - therapeutic use (279) 279
antithrombins - therapeutic use (274) 274
risk assessment (272) 272
warfarin - administration & dosage (270) 270
retrospective studies (268) 268
antithrombins - administration & dosage (253) 253
beta-alanine - administration & dosage (250) 250
pyridines - adverse effects (249) 249
dabigatran - administration & dosage (248) 248
thromboembolism - prevention & control (248) 248
venous thromboembolism - prevention & control (245) 245
cardiology (239) 239
efficacy (238) 238
patients (235) 235
surgery (235) 235
mortality (234) 234
adult (232) 232
dosage and administration (232) 232
thrombosis (228) 228
pyridines - therapeutic use (225) 225
randomized controlled trials as topic (225) 225
rivaroxaban - adverse effects (224) 224
double-blind (221) 221
pyrazoles - administration & dosage (216) 216
pyridones - administration & dosage (216) 216
edoxaban (212) 212
internal medicine (211) 211
pharmacokinetics (207) 207
enoxaparin (206) 206
reversal (204) 204
thiophenes - therapeutic use (204) 204
antithrombotic therapy (202) 202
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2880) 2880
German (86) 86
French (38) 38
Spanish (33) 33
Russian (27) 27
Danish (8) 8
Japanese (6) 6
Czech (5) 5
Hungarian (4) 4
Norwegian (4) 4
Swedish (4) 4
Polish (3) 3
Turkish (3) 3
Dutch (2) 2
Finnish (2) 2
Italian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
by Schulman, Sam and Kakkar, Ajay K and Goldhaber, Samuel Z and Schellong, Sebastian and Eriksson, Henry and Mismetti, Patrick and Christiansen, Anita Vedel and Friedman, Jeffrey and Le Maulf, Florence and Peter, Nuala and Kearon, Clive and Schulman, S and Eriksson, H and Goldhaber, S and Kakkar, A and Kearon, C and Mismetti, P and Schellong, S and Bergqvist, D and Tijssen, J and Prins, M. [=Martin H.] and Robben, S and Büller, H and Otten, H. M and Brandjes, D and Peters, R and Mac Gillavry, M. R and Gan, E and Salem, H and Baker, R and Blomberry, P and Curnow, J and Annichino-Bizzacch, J. M and Brandao Panico, M. D and Timi Ribas, J. R and Fernandes Manenti, E. R and Miranda, F and Moraes, J and Raev, D and Mollov, M and Peneva, M and Milanov, S and Anderson, D and Crowther, M and Dolan, S and Eikelboom, J and Game, M and Kahn, S and Kassis, J and Ritchie, B and Solymoss, S and Rodger, M and Yeo, E and Milot, A and Klinke, P and Chen, W and Zhihong, L and Chunxue, B and Jinming, L and Jiwei, Z and Jie, C and Jina, K and Yuqi, W and Zhongqi, Y and Hua, W and Kejing, Y and Bonan, L and Yadong, Y and Changwei, L and Jin, Z and Yongcheng, D and Spinar, J and Maly, R and Cizek, V and Bercikova, J and Cervinka, P and Lang, P and Jirka, V and Oral, I and Reichert, P and Kotik, L and Pojsl, S and Klimovic, T and Husted, S and Nielsen, H and Friis, E and Skødebjerg Kristensen, K and Mottier, D and El Kouri, D and Bleher, Y and Leroux, L and Boda, Z and Sereg, M and Riba, M and Hiremath, J. S and Kareem, S and Banker, D. N and Gadkari, M and Parakh, R and Suresh, K. R and ... and RE-COVER II Trial Investigators
Circulation, ISSN 0009-7322, 2014, Volume 129, Issue 7, pp. 764 - 772
Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those... 
Antagonists & inhibitors | Recurrence | Thrombin | Warfarin | Hemorrhage | Venous thromboembolism | CARDIAC & CARDIOVASCULAR SYSTEMS | FONDAPARINUX | THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | RIVAROXABAN | INITIAL TREATMENT | PERIPHERAL VASCULAR DISEASE | ORAL ANTICOAGULANT-THERAPY | APIXABAN | UNFRACTIONATED HEPARIN | Anticoagulants - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Warfarin - adverse effects | Male | Antithrombins - administration & dosage | Dabigatran | Heparin - adverse effects | Warfarin - administration & dosage | Venous Thromboembolism - drug therapy | Young Adult | Benzimidazoles - administration & dosage | Adult | Female | Benzimidazoles - adverse effects | Venous Thromboembolism - epidemiology | beta-Alanine - analogs & derivatives | Acute Disease | beta-Alanine - adverse effects | Double-Blind Method | Hemorrhage - epidemiology | Risk Factors | beta-Alanine - administration & dosage | Anticoagulants - adverse effects | Antithrombins - adverse effects | Adolescent | Aged | Hemorrhage - chemically induced | Heparin, Low-Molecular-Weight - administration & dosage | Usage | Care and treatment | Dabigatran etexilate | Thromboembolism | Index Medicus | Abridged Index Medicus | Anticoagulants | Benzimidazoles | Heparin, Low-Molecular-Weight | Life Sciences | Venous Thromboembolism | Antithrombins | Heparin | beta-Alanine
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 16, pp. 1513 - 1524
In this trial, dabigatran plus a P2Y 12 inhibitor was compared with warfarin plus a P2Y 12 inhibitor and aspirin after PCI in patients with atrial... 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | HEART-DISEASE | MYOCARDIAL-INFARCTION | ORAL ANTICOAGULATION | 2011 ACCF/AHA/SCAI GUIDELINE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | TRIPLE THERAPY | ANTIPLATELET THERAPY | CONSENSUS DOCUMENT | Dabigatran - adverse effects | Ticlopidine - therapeutic use | Humans | Middle Aged | Warfarin - adverse effects | Male | Risk | Dabigatran - therapeutic use | Incidence | Warfarin - therapeutic use | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Therapy, Combination - adverse effects | Adenosine - adverse effects | Adenosine - therapeutic use | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Ticagrelor | Purinergic P2Y Receptor Antagonists - therapeutic use | Hemorrhage - epidemiology | Atrial Fibrillation - drug therapy | Atrial Fibrillation - therapy | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Ticlopidine - analogs & derivatives | Adenosine - analogs & derivatives | Clopidogrel | Aged | Hemorrhage - chemically induced | Percutaneous Coronary Intervention | Warfarin | Atrial fibrillation | Dosage and administration | Research | Thromboembolism | Hemorrhage | Health aspects | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Embolisms | Preventive medicine | Thrombosis | Bleeding | Embolism | Fibrillation | Cardiology | Drug therapy | Drug dosages | Geriatrics | Index Medicus | Abridged Index Medicus | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Journal Article
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 03/2012, Volume 107, Issue 3, pp. 584 - 589
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 6, pp. 511 - 520
Journal Article
Journal of the American Heart Association, ISSN 2047-9980, 06/2016, Volume 5, Issue 6, p. n/a
Journal Article